urc mondor

Unité de Recherche Clinique Henri Mondor

Accuracy of the G-8 geriatric-oncology screening tool for identifying vulnerable elderly patients with cancer according to tumour site: the ELCAPA-02 study.

Liuu E, Canoui-Poitrine F, Tournigand C, Laurent M, Caillet P, Le Thuaut A, Vincent H, Culine S, Audureau E, Bastuji-Garin S, Paillaud E J Geriatr Oncol. 2014;5(1):11-9.

<p><b>BACKGROUND/OBJECTIVE: </b>G-8 screening tool showed good screening properties for identifying vulnerable elderly patients with cancer who would benefit from a comprehensive geriatric assessment (CGA). We investigated whether tumour site and metastatic status affected its accuracy.</p><p><b>DESIGN: </b>Cross-sectional analysis of a prospective cohort study.</p><p><b>SETTING: </b>Geriatric-oncology clinics of two teaching hospitals in the urban area of Paris.</p><p><b>PARTICIPANTS: </b>Patients aged 70 or over (n = 518) with breast ( n= 113), colorectal (n = 108), urinary-tract (n = 89), upper gastrointestinal/liver (n = 85), prostate (n = 69), or other cancers (n = 54).</p><p><b>MEASUREMENTS: </b>Reference standard for diagnosing vulnerability was the presence of at least one abnormal test among the Activities of Daily Living (ADLs), Instrumental ADL, Mini-Mental State Examination, Mini Nutritional Assessment, Cumulative Illness Rating Scale-Geriatrics, Timed Get-Up-and-Go, and Mini-Geriatric Depression Scale. Sensitivity, specificity and likelihood ratios of G-8 scores ≤ 14 were compared according to tumour site and patient characteristics.</p><p><b>RESULTS: </b>Median age was 80; 48.2% had metastases. Prevalence of vulnerability and abnormal G-8 score was 84.2% (95% confidence interval [95% CI], 81-87.3) and 79.5% (95% CI, 76-83). The G-8 was 86.9% sensitive (95% CI, 83.4-89.9) and 59.8% specific (95% CI, 48.3-70.4). G-8 performance varied significantly (all p values < 0.001) across tumour sites (sensitivity, 65.2% in prostate cancer to 95.1% in upper gastrointestinal/liver cancer; and specificity, 23.1% in colorectal cancer to 95.7% in prostate cancer) and metastatic status (sensitivity and specificity, 93.8% and 53.3% in patients with metastases vs. 79.5% and 63.3% in those without, respectively). Differences remained significant after adjustment on age and performance status.</p><p><b>CONCLUSION: </b>These G-8 accuracy variations across tumour sites should be considered when using G-8 to identify elderly patients with cancer who could benefit from CGA.</p>

MeSH terms: Aged; Aged, 80 and over; Cross-Sectional Studies; Early Detection of Cancer; Female; Geriatric Assessment; Humans; Male; Neoplasms; Prospective Studies; Reference Standards; Sensitivity and Specificity; Vulnerable Populations
DOI: 10.1016/j.jgo.2013.08.003